

RESEARCH ARTICLE

Open Access



Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer

Xuyao Zhang^{1,2,3†}, Yichen Wang^{1,2†}, Jiajun Fan^{1,2}, Wei Chen^{1,2}, Jingyun Luan^{1,2}, Xiaobin Mei⁴, Shaofei Wang^{2,3}, Yubin Li^{2,3}, Li Ye², Song Li⁵, Wenzhi Tian⁵, Kai Yin^{4*} and Dianwen Ju^{1,2*} 

Abstract

Background: Inhibitors targeting VEGF and VEGFR are commonly used in the clinic, but only a subset of patients could benefit from these inhibitors and the efficacy was limited by multiple relapse mechanisms. In this work, we aimed to investigate the role of innate immune response in anti-angiogenic therapy and explore efficient therapeutic strategies to enhance efficacy of anti-angiogenic therapy against non-small cell lung cancer (NSCLC).

Methods: Three NSCLC tumor models with responses to VEGF inhibitors were designed to determine innate immune-related underpinnings of resistance to anti-angiogenic therapy. Immunofluorescence staining, fluorescence-activated cell sorting and immunoblot analysis were employed to reveal the expression of immune checkpoint regulator CD47 in refractory NSCLC. Metastatic xenograft models and VEGFR1-SIRPα fusion protein were applied to evaluate the therapeutic effect of simultaneous disruption of angiogenetic axis and CD47-SIRPα axis.

Results: Up-regulation of an innate immunosuppressive pathway, CD47, the ligand of the negative immune checkpoint regulator SIRPα (signal regulatory protein alpha), was observed in NSCLC tumors during anti-angiogenic therapy. Further studies revealed that CD47 upregulation in refractory lung tumor models was mediated by TNF-α/NF-κB1 signal pathway. Targeting CD47 could trigger macrophage-mediated elimination of the relapsed NSCLC cells, eliciting synergistic anti-tumor effect. Moreover, simultaneously targeting VEGF and CD47 by VEGFR1-SIRPα fusion protein induced macrophages infiltration and sensitized NSCLC to angiogenesis inhibitors and CD47 blockade.

Conclusions: Our research provided evidence that CD47 blockade could sensitize NSCLC to anti-angiogenic therapy and potentiate its anti-tumor effects by enhancing macrophage infiltration and tumor cell destruction, providing novel therapeutics for NSCLC by disrupting CD47/SIRPα interaction and angiogenetic axis.

Keywords: Anti-angiogenesis, VEGF, CD47, Immunotherapy, Bispecific therapy

Background

Sustained angiogenesis is an important hallmark of non-small cell lung cancer (NSCLC) [1]. A series of molecules has been identified to play crucial roles in angiogenesis and vasculogenesis, and most studies to date were focused on VEGFR (vascular endothelial growth factor receptor) and

its ligand VEGF [2, 3]. The biological functions of VEGF and VEGFR in tumor angiogenesis provided a convincing principle for the development of inhibiting agents targeting VEGF-VEGFR axis [4]. Since the last decades, more than ten anti-angiogenic therapeutics including bevacizumab, regorafenib and sorafenib have been approved for the therapy against several malignant diseases [3–5]. Unfortunately, due to the unknown relapse mechanisms, beneficial effects of these drugs used as monotherapy or in combination with chemotherapy are only observed in limited number of patients [6–8]. Here, in this context, we aimed to elucidate novel relapse mechanisms underlying the

* Correspondence: kyin67@smmu.edu.cn; dianwenju@fudan.edu.cn

[†]Xuyao Zhang and Yichen Wang contributed equally to this work.

⁴Changhai Hospital, Second Military Medical University, Shanghai 200433, China

¹Minhang Hospital, Fudan University, 170 Xinsong Road, Shanghai 201199, China

Full list of author information is available at the end of the article



anti-angiogenic therapy and provide efficient strategy to enhance the anti-tumor effect of anti-angiogenic treatment.

Studies of tumor immune microenvironment reveal that tumors evade immune system detection through developing the local angiogenic vasculature [9–12]. Angiogenic vasculature in tumors thwarts the extravasation of tumor-responsive lymphocytes and develops an immunosuppressive microenvironment that confers tumors to evade host's immune surveillance [10, 13]. Increased VEGF in tumors impairs lymphocyte-endothelial interaction by decreasing intercellular cell adhesion molecules in neovascularization to block immune cells infiltration into the tumors [10]. Besides, VEGF can directly trigger regulatory T cells proliferation and inhibit the maturation of dendritic cells [14]. Stimulation of the host's immune system with immune checkpoint inhibitors showed robust anti-tumor effects and hold promise for the treatment of malignant tumors [15, 16]. Considering the facts that tumor immune microenvironment is bound up with tumor angiogenic vasculature, effort has been made to investigate the relationship between anti-angiogenic therapy and tumor immunotherapy [17–19]. It was reported that anti-tumor effect of VEGF/VEGFR inhibitors was dependent on their abilities to elicit an immune-activated milieu in breast and pancreatic tumors. Combinational use of anti-PD-L1 treatment sensitized tumors to VEGF/VEGFR blockade and prolonged anti-tumor effect [9]. However, the important role of innate immune response, especially macrophage, in anti-angiogenic therapy was still unknown.

CD47 (Cluster of differentiation 47)/SIRP α (signal-regulatory protein alpha), an innate negative immune regulatory axis that transmits "don't eat me" signal to macrophages and confers tumor cells resistant to immune surveillance [20–23]. CD47/SIRP α -based therapies have been proven as an effective treatment for solid tumors and hematologic malignancies, with several clinical trials including CD47-blocking monoclonal antibodies or SIRP α -Fc fusion protein [24–26]. These findings highlighted the great impetus in tumor immunotherapy to mobilize macrophages to participate in anti-tumor activities. Compared with other isomers of the VEGFR family, VEGFR1 showed very high binding affinity to VEGF and functioned as a decoy receptor to VEGF [4]. Aflibercept, a soluble chimeric protein based on the extracellular domain of VEGFR1, has been approved for the therapy of colorectal cancer [2]. In this context, we found for the first time that the unsustainable efficacy of anti-angiogenic therapy was resulted from their ability to upregulate CD47 expression in tumor microenvironment conferring NSCLC resistant to anti-angiogenic therapy. Administration of VEGF-VEGFR inhibitor VEGFR1-Fc in combination with CD47 blocking fusion protein generated synergistic antitumor

efficacy, highlighting the potential therapeutic strategies for NSCLC via blocking angiogenetic axis and CD47/SIRP α anti-phagocytic axis.

Methods

Reagents

Reagents and antibodies were obtained as follows: anti-CA9 antibody (Novus Biologicals, Littleton, USA), carboxyfluorescein diacetate succinimidyl ester (CFDA SE) (Beyotime Biotech, Hangzhou, China), FITC-labeled anti-NF- κ B1, PE-labeled anti-CD47, PerCP/Cyanine5.5-labeled anti-CD31, Alexa Fluor 488-labeled anti-CD11b, PE-labeled F4/80 and APC-labeled anti-CD45 antibodies (Biolegend, San Diego, USA), Bevacizumab (Roche Genentech, South San Francisco, USA). BAY 11–7082 (Selleckchem, Shanghai, China). Clodronate liposomes (FormuMax Scientific, Inc., Sunnyvale, USA). SIRP α -Fc fusion protein was expressed as previously described [27]. VEGFR1-SIRP α is based on the first extracellular domain of SIRP α and the second extracellular domain of VEGFR1. SIRP α -VEGFR1 expression cassette sequence was synthesized (GenBank accession number: MG920788), expressed and purified from CHO cells.

Cell lines and culture conditions

NCI-H1975, A549 and LLC (Lewis Lung Carcinoma) cells were purchased from Cell Bank of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and authenticated by short tandem repeat fingerprinting in the cell bank. Cells were cultured in medium with 10% FBS (Gibco, San Diego, USA) and passaged less than 6 months upon receipt.

Fluorescence-activated cell sorting

VEGFR1-Fc was intraperitoneally injected into tumor-bearing mice twice a week for 4 weeks. Tumors were then harvested and processed into a single-cell suspension. Cells were treated with Fc-blocking antibody, stained with PerCP/Cyanine5.5-labeled anti-CD31, APC-labeled anti-CD45 and PE/Cyanine 7-labeled anti-keratin antibodies. Endothelial cells were sorted as CD45⁻CD31⁺keratin⁻ cells. Immune cells were identified as CD45⁺CD31⁻keratin⁻ cells and tumor cells were sorted as CD45⁻CD31⁻keratin⁺ cells. To isolate NF- κ B1⁺ cells from tumors and sort them into endothelial cells, immune cells and tumor cells, cells were collected and stained with PerCP/Cyanine5.5-labeled anti-CD31 and APC-labeled anti-CD45 antibodies. The cells were then fixed with 4% paraformaldehyde and permeabilized with triton X-100, and then stained with FITC-labeled anti-NF- κ B1 antibody. Analyses of sorted cells from tumor-bearing mice were performed using at least three independent mice for each treatment condition.

Phagocytosis and cytotoxicity assay

Macrophage phagocytosis and cytotoxicity were detected as described previously [26, 28]. Briefly, primary mouse macrophages were obtained from femurs of BALB/c nude mice and cultured in medium containing macrophage colony-stimulating factor (100 ng/ml) and FBS (10%). One week later, macrophages were collected and co-cultured with CFDA SE-labeled NSCLC cells. After SIRP α -Fc treatment, confocal microscopy was used to calculate the phagocytic index. Cytotoxicity was examined by CytoTox 96[®] Non-Radio. Cytotoxicity Assay (Promega, Madison, USA) at different effector: target cell ratio.

Immunoblot analysis

After VEGFR1-Fc treatment, NSCLC tumor tissues were harvested and homogenized with RIPA lysis buffer. Equivalent amounts of the extracted protein were analyzed by SDS-PAGE gel electrophoresis. ImageJ Software was used to quantify densitometric values of resulting bands.

Tumor models

To construct subcutaneous xenograft models, BALB/c nude mice (6 weeks old) were subcutaneously inoculated with NSCLC cells (5×10^6). To establish metastatic xenograft models, Nude mice were injected with NSCLC cells (1×10^6) via the tail vein. To construct syngeneic immunocompetent model, C57BL/6 mice were subcutaneously inoculated with 1×10^6 of LLC cells. VEGFR1-Fc (10 mg/kg), SIRP α -Fc (10 mg/kg) and VEGFR1-SIRP α (10 mg/kg) were injected intraperitoneally twice a week. BAY 11-7082 (5 mg/kg) was injected intraperitoneally three times a week. Clo/liposome (200 μ l per mouse) was injected intraperitoneally twice a week.

Statistical analysis

GraphPad Prism 7 was employed to analyze the data. Comparison in this study was performed by Student's *t*-test or One-Way ANOVA analysis. *P* value < 0.05 was regarded as statistical significance.

Results


CD47 expression increased in NSCLC relapsing from anti-angiogenic treatment

To determine innate immune-related underpinnings of resistance to anti-angiogenic treatment in NSCLC, we used A549, NCI-H1975 and LLC tumor models with responses to VEGF inhibitors. As shown in (Additional file 1: Figure S1), anti-angiogenic treatment (VEGFR1-Fc fusion protein, or anti-VEGF antibody bevacizumab) could tentatively control tumor growth for about 2 to 3 weeks followed by resistance to anti-angiogenic therapy and robust tumor growth, and finally did not elicit significant

survival benefits (Additional file 2: Figure S2). Immunofluorescence staining of immune checkpoint regulator in NSCLC models revealed a significant increased expression of CD47 in refractory NSCLC (Fig. 1a and b, Additional file 3: Figure S3, and Additional file 4: Figure S4). Fluorescence-activated cell sorting (FACS) and immunoblot analysis showed that tumor cells were the primary source of CD47 increased cells in NSCLC (Fig. 1c and d, and Additional file 5: Figure S5). In brief, these data showed that CD47 was up-regulated by anti-angiogenic therapy in a tumor cell-specific manner.

Anti-angiogenic therapy increased CD47 via TNF- α /NF- κ B1

Then, we sought to investigate how VEGF inhibitor increased CD47 expression on NSCLC cells. Considering the fact that anti-angiogenic therapy could reduce vessel density and induce hypoxic areas and inflammation in tumors, we, at first, isolated tumor cells from NSCLC xenograft tumors in the mice treated with/without VEGFR1-Fc fusion protein continuously for 4 weeks. Staining with antibodies against the hypoxia-regulated CA9 (carbonic anhydrase IX) and CD47 were employed to evaluate the ratio of hypoxia NSCLC cells that displayed CD47 expression. Although VEGF inhibitor increased tumor hypoxia in A549 and NCI-H1975 xenograft models, there are only 4 to 6% of total CA9⁺ cells that were CD47⁺, demonstrating that hypoxia was not the major cause of CD47 upregulation during anti-angiogenic therapy (Fig. 2a). Because NF- κ B1 transcription factor was one regulator that directly regulated CD47 expression, we examined the percentage of NF- κ B1⁺ cells in this population and detected the co-localization of NF- κ B1 and CD47. We found that 40 to 60% NF- κ B1⁺ tumor cells were CD47⁺ (Fig. 2b-d). Then we isolated NF- κ B1⁺ cells from these two xenograft models and sorted them into endothelial cells, immune cells and tumor cells, and researched the expression profile of the upstream of NF- κ B1: TNF- α (tumor necrosis factor- α). As shown in Fig. 2e and f, VEGF blockade also substantially enhanced TNF- α expression in relapsing tumor cells. In addition, data from syngeneic immunocompetent tumor model also showed that VEGFR1-Fc treatment increased TNF- α /NF- κ B1 pathway in refractory LLC tumors (Additional file 6: Figure S6). To evaluate the possible role of TNF- α /NF- κ B1 pathway in anti-angiogenic therapy-induced CD47 upregulation, the tumor-bearing mice were simultaneously treated with VEGF inhibitor and BAY 11-7082 (TNF- α /NF- κ B1 inhibitor). After TNF- α /NF- κ B1 being successfully abrogated by BAY 11-7082, anti-angiogenic treatment-induced CD47 upregulation was diminished in NSCLC tumors and produced increased anti-tumor effect (Fig. 3a and b, Additional file 6: Figure S6).




These results demonstrated that TNF- α /NF- κ B1 signaling pathway was involved in VEGF/VEGFR blockade-induced CD47 expression.

CD47-SIRP α inhibition potentiated response to VEGF blockade in NSCLC

Then, we speculated that inhibition of CD47 could be sufficient to extend an anti-tumor response during anti-angiogenic treatment. To examine this proposition, we treated NSCLC xenograft mice with VEGFR1-Fc alone or in combination with SIRP α -Fc. After a temporal remission, tumors became refractory

as characterized by increased tumor burden after 2 to 3 weeks of VEGFR1-Fc treatment. In contrast, comparable to VEGFR1-Fc monotherapy, anti-angiogenic therapy in combination with CD47 blockade inhibited tumor regrowth and resulted in a low tumor burden (Fig. 4). In A549 xenograft model, tumor weight in VEGFR1-Fc group was 426.04 ± 64.26 mg versus 942.20 ± 130.27 mg of the isotype control ($P < 0.0001$) (Fig. 4a), and the tumor weight in VEGFR1-Fc and SIRP α -Fc co-treatment group was 68.15 ± 35.64 mg ($P < 0.0001$ versus VEGFR1-Fc group). In NCI-H1975 tumor model, tumor weight in mice co-treated with





VEGFR1-Fc and SIRP α -Fc was 56.08 ± 32.09 mg ($P < 0.0001$ versus VEGFR1-Fc cohort), while the tumor weight in VEGFR1-Fc group and the control were 412.15 ± 51.19 mg and 818.09 ± 97.57 mg, respectively (Fig. 4b). In LLC tumor models, tumor weight in VEGFR1-Fc and SIRP α -Fc co-treatment group was 15.11 ± 9.03 mg versus 320.02 ± 43.3 mg of VEGFR1-Fc group ($P < 0.0001$) (Fig. 4c).


In brief, these results showed that blocking CD47 by SIRP α -Fc potentiated anti-tumor response of NSCLC to VEGF blockade.

Targeting CD47 increased macrophage phagocytosis of NSCLC cells relapsing from anti-angiogenic therapy

The NF- κ B1 response in NSCLC undergoing VEGF/VEGFR blockade induced a negative feedback loop. The feedback loop increased CD47 expression that deactivated macrophage activity via binding to SIRP α , thereby rendering tumors more immunosuppressive. Then, we

isolated tumor cells from NSCLC tumors in VEGFR1-Fc-treated mice and investigated whether targeting CD47 could eliminate the relapsing NSCLC cells. SIRP α -Fc fusion protein was used to disrupt CD47-SIRP α axis. SIRP α -Fc alone showed negligible effects on the cell viability (data not shown). While SIRP α -Fc could increase macrophage cytotoxicity against the relapsing NSCLC cells (Fig. 5a). Compared with isotype control IgG1-Fc, SIRP α -Fc increased the phagocytic index from 6.0 to 27.0, from 8.0 to 29.0 and from 6.0 to 23.0 in the A549 cells, NCI-H1975 cells and LLC cells relapsing from anti-angiogenic therapy, respectively (Fig. 5b). Furthermore, to detect the relevant of macrophages and CD47 in vivo, Clo/liposome (clodronate liposome) was employed to deplete macrophages in NSCLC xenograft model (Fig. 5c). Compared with the negative control PBS/liposome, Clo/liposome accelerated the tumor growth of mice treated with SIRP α -Fc (Fig. 5d, e and Additional file 7: Figure S7a). Tumor weight in PBS/





liposome + IgG1-Fc group, PBS/liposome + VEGFR1-Fc group, PBS/liposome + SIRP α -Fc group, PBS/liposome + VEGFR1-Fc + SIRP α -Fc group were 916.62 ± 113.49 mg, 516.00 ± 78.29 mg, 360.20 ± 68.34 mg, 112.12 ± 28.84 mg. While tumor weight in Clo/liposome + IgG1-Fc group, Clo/liposome + VEGFR1-Fc group, Clo/liposome + SIRP α -Fc group and Clo/liposome + VEGFR1-Fc + SIRP α -Fc group were 950.01 ± 147.82 mg, 528.16 ± 134.24 mg, 814.66 ± 145.58 mg and 513.98 ± 84.44 mg. These data showed that macrophage depletion totally abrogated the anti-tumor effect of SIRP α -Fc.

In addition, syngeneic immunocompetent tumor model was established to confirm the relevant of macrophage and CD47 was also evaluated in LLC tumors. We

found that Clo/liposome recovered the tumor burden in mice treated with SIRP α -Fc. Tumor weight in Clo/liposome + SIRP α -Fc group was 580.02 ± 76.82 mg versus 236.86 ± 39.45 mg of PBS/liposome + SIRP α -Fc group ($P < 0.001$), and tumor weight in Clo/liposome + VEGFR1-Fc + SIRP α -Fc group was 355.78 ± 98.91 mg versus 67.54 ± 41.18 mg of PBS/liposome + VEGFR1-Fc + SIRP α -Fc group ($P < 0.001$). While the tumor weight in Clo/liposome + IgG1-Fc group and PBS/liposome + IgG1-Fc group were 632.16 ± 55.96 mg and 628.38 ± 86.98 mg, respectively (Fig. 5f and Additional file 7: Figure S7). These results uncovered that blocking CD47 by SIRP α -Fc could induce effective macrophage-mediated elimination of the relapsing NSCLC cells.

Co-targeting CD47 and VEGF elicited synergetic anti-tumor effect in NSCLC and prolonged the median survival


Next, we aimed to evaluate the therapeutic effects of simultaneous disruption of angiogenetic axis and CD47/SIRP α axis in NSCLC. VEGFR1-SIRP α fusion protein was employed to target CD47 and VEGF simultaneously. In A549 xenograft model, tumor volume presented that targeting VEGF and CD47 by VEGFR1-SIRP α could elicited potent anti-tumor effect (Fig. 6a). After 27 days' treatment, tumor weight in the groups of isotype control and VEGFR1-SIRP α were 802.05 \pm 95.98 mg and 30.20 \pm 34.64 mg, respectively. Similarly, in NCI-H1975 tumor model, tumor weight in the groups of isotype control and VEGFR1-SIRP α were 768.11 \pm 107.56 mg and 32.00 \pm 23.87 mg, respectively (Fig. 6b). Microvessels-specific marker CD31 was used to determine microvessel density and Fig. 6c and d presented that blocking CD47 potentiated the anti-angiogenic effects of VEGFR1-Fc ($P < 0.01$). In Fig. 7a, Additional file 8: Figure S8 and Additional file 9: Figure S9 histopathological analysis and flow cytometry plots demonstrated that VEGFR1-SIRP α elicited prominent macrophage infiltration without significant VEGFA production. Dendritic cells were also involved in CD47 blockade-induced anti-tumor effect in NSCLC (Additional file 9: Figure S9b). To assess whether blocking angiogenetic axis and CD47/SIRP α could extend the survival, two metastatic models were established. In A549 metastatic model, compared to the isotype control, VEGFR1-Fc showed no significant effect

on the median survival. SIRP α -Fc group had a median survival of 60 days, whereas VEGFR1-SIRP α could extend the median survival to 85 days (Fig. 7b). In NCI-H1975 metastatic model, median survival of the mice treated with isotype control, VEGFR1-Fc, SIRP α -Fc, VEGFR1-SIRP α were 46 days, 54 days, 59 days and 89 days, respectively (Fig. 7c).

These data showed that blocking angiogenetic axis and CD47/SIRP α axis elicited synergetic anti-tumor effect in NSCLC and significantly prolonged the median survival via anti-angiogenesis and macrophage activation.

Discussion

Although anti-angiogenic therapy could improve progression-free survival (PFS) in some NSCLC patients, but overall survival (OS) is modestly improved and most patients are unfortunately short-lived [6, 29–32]. Here, we revealed the up-regulation of CD47, the negative checkpoint molecule that binds to SIRP α , as an innate immunosuppressive mechanism that limited the anti-tumor effect of VEGF/VEGFR inhibitors. During the anti-angiogenic therapy, a negative feedback was created by upregulating CD47 to inactivate macrophage phagocytosis. Simultaneous blockade of angiogenetic axis and CD47/SIRP α axis significantly improved anti-tumor efficacy and prolonged median survival in NSCLC-bearing mice, which was most likely mediated through facilitating enhanced macrophage infiltration and producing successful extermination of experimental NSCLC.






Fig. 7 Targeting CD47 and VEGF significantly prolonged the median survival of NSCLC-bearing mice. **a** Immunohistochemistry CD68 staining of NCI-H1975 tumor tissues. **b** and **c** A549 metastatic model (**b**) and NCI-H1975 metastatic model (**c**) were constructed to challenge the effects of VEGFR1-SIRP α on the survival ($N = 5$ per group). **d** The description of combined anti-angiogenic and CD47-blocking therapies eliciting potent anti-tumor effect in NSCLC

Previous studies have reported that reinstating tumor growth by neovascularization or by modifying the growth behavior could help malignancy adapt to the limit of vascular growth restriction [10]. It has been demonstrated that these adaptations could also be regulated by the host immune system, which provided additional cytokines and chemokines that promoted angiogenesis and immunosuppression [33–35]. The expression of VEGF-A and PD-1/PD-L1 in lymph nodes of 103 patients were quantified and the data showed the higher positivity of VEGF-A and PD-1 in metastatic nodes and the surrounding negative nodes in comparison with non-metastatic patients [36]. Notably, in pancreatic (RT2-PNET, pancreatic neuroendocrine tumors), breast (PyMT, polyoma middle T oncoprotein) and brain (GBM, glioblastoma) tumor mouse models,

expression of PD-L1, the ligand of PD-1, was enhanced by interferon- γ -expressing T cells in tumors relapsed from VEGF-A inhibition [9]. The above studies mainly focused on investigating the adaptive immune system in anti-angiogenic therapy. In the current work, we studied the important role of innate immune response in anti-angiogenic therapy and described for the first time that the upregulation of CD47 as a result of anti-angiogenic therapy plays an important role in relapsing NSCLC.

Our study showed that anti-angiogenic treatment-induced negative feedback, facilitating the interaction of CD47⁺ NSCLC cells with innate immune cells, was in line with the previous observation that the anti-tumor effects of anti-angiogenic therapy depended on the immunostimulatory environment formation [16]. As a key anti-phagocytic axis, CD47-SIRP α connection

transfers “don’t eat me” signal to macrophage and inactivates macrophage phagocytosis, rendering cancer cell resistant to host’s innate immune monitoring [37]. Disrupting CD47/SIRP α signaling transduction by blocking antibodies (Hu5F9-G4 and CC-90002) could increase macrophage phagocytosis of multiple tumor cells and has been proved as a promising immunotherapeutic method for melanoma, breast cancer, small cell lung cancer and acute myeloid leukemia [38, 39]. Late-breaking studies reported that targeting CD47 by SIRP α -based fusion protein increased macrophage-mediated elimination of NSCLC and glioblastoma cells [25, 26]. Consistent with these studies, SIRP α -Fc was used to block the increased CD47 and was shown to trigger macrophage phagocytosis and cytotoxicity against NSCLC cells relapsing from anti-angiogenic treatment. Mechanistically, the combination of anti-angiogenic treatment and CD47 blockade could counteract the anti-angiogenic treatment-induced immunosuppressive pathway (CD47 up-regulation), and it was conceivable that CD47 blockade recruited and activated macrophages during anti-angiogenic therapy, eliciting enhanced anti-tumor efficacy.

Furthermore, coinstantaneous blocking VEGF and CD47 by VEGFR1-SIRP α fusion protein induced macrophages infiltration and CD47 blockade sensitized tumors to anti-angiogenic therapy. However, one important question that has yet to be answered is: what was the mechanism by which CD47 became upregulated on NSCLC cells relapsing from anti-angiogenic therapy. To answer this question, we isolated tumor cells from NSCLC tumors in VEGFR1-Fc-treated mice to elucidate the underlying mechanism. For the first time, we revealed that VEGF/VEGFR blockade-increased CD47 expression was dependent on the activation of TNF- α /NF- κ B1 signaling pathway. Our results were consistent with previous study indicating that CD47 was regulated by sets of pro-inflammatory super-enhancers in breast cancer, diffuse large B-cell lymphoma and acute lymphoblastic leukemia [40].

Conclusions

This study demonstrated that the up-regulation of an innate immunosuppressive pathway was served as a resistant mechanism during anti-angiogenic therapy, by which CD47 was enhanced via TNF- α /NF- κ B1 signal pathway in refractory lung tumor models following anti-angiogenic therapy. Simultaneously disrupting CD47/SIRP α anti-phagocytic axis and VEGF/VEGFR angiogenic axis elicited macrophages infiltration and sensitized tumors to anti-angiogenic therapy (Fig. 7d). These results provided a novel insight into the resistant mechanisms in anti-angiogenic therapy, facilitating clinic application of VEGF/VEGFR inhibitors in combination with CD47-targeting immune checkpoint inhibitors.

Supplementary information

Supplementary information accompanies this paper at <https://doi.org/10.1186/s40425-019-0812-9>.

Additional file 1: Figure S1. The anti-tumor effects of VEGF/VEGFR inhibitors in NSCLC.

Additional file 2: Figure S2. NSCLC metastasis models were constructed to assess the effect of VEGFR1-Fc on the survival.

Additional file 3: Figure S3. The expression of CD47 on NSCLC cells was detected by flow cytometry.

Additional file 4: Figure S4. CD47 expression was up-regulated by VEGF inhibitor in A549, NCI-H1975 and LLC tumors.

Additional file 5: Figure S5. The CD47 expression was up-regulated by VEGF inhibitor in different cell constituents in a tumor type-specific manner.

Additional file 6: Figure S6 Targeting TNF- α /NF- κ B1 reversed VEGFR1-Fc-induced CD47 upregulation in LLC tumors.

Additional file 7: Figure S7. SIRP α -Fc induced potent macrophage-mediated elimination of NSCLC cells.

Additional file 8: Figure S8. Flow cytometry profile of macrophages in NSCLC tumors treated with VEGFR1-Fc and/or SIRP α -Fc.

Additional file 9: Figure S9. (a) FACS analysis was employed to sort CD68⁺ macrophages from LLC tumor and the VEGFA level in CD68⁺ macrophage was measured. SIRP α -Fc enhanced macrophage infiltration without significant VEGFA production in the tumors. (b) CD11c was used as a marker to detect dendritic cells in LLC tumor treated with SIRP α -Fc or VEGFR1-SIRP α .

Abbreviations

CD47: Cluster of differentiation 47; CFDA SE: Carboxyfluorescein diacetate succinimidyl ester; GBM: Glioblastoma; LLC: Lewis Lung Carcinoma; NSCLC: Non-small cell lung cancer; OS: Overall survival; PFS: Progression-free survival; SIRP α : Signal regulatory protein alpha; VEGFR: Vascular endothelial growth factor receptor

Acknowledgements

Not applicable.

Authors’ contributions

KY and DJ designed the experiments and proofread the manuscript. XZ, YW, JF, WC and JL performed the experiments and prepared the manuscript. XM, SW, YL, LY, SL and WT provided material and analyzed the data. All authors read and approved the final manuscript.

Funding

This work was supported by grants from National Key Basic Research Program of China (2015CB931800), the National Natural Science Foundation of China (81773620, 81573332 and 31872746), Shanghai Science and Technology Funds (18431902800), the Scientific Research Projects of Shanghai Municipal Commission of Health and Family Planning (201740140).

Availability of data and materials

All data generated and analyzed during this study are included in this published article and its supplementary information.

Ethics approval and consent to participate

Procedures involving BALB/c nude mice and C57BL/6 mice (six-week old, male) were performed in accordance with the standards of Fudan University and approved by Animal Ethical Committee of School of Pharmacy Fudan University.

Consent for publication

Not applicable.

Competing interests

Song Li is the employee, and Wenzhi Tian is the founder of ImmuneOnco Biopharma (Shanghai) Co., Ltd. The other authors declare no conflict of interests.

Author details

¹Minhang Hospital, Fudan University, 170 Xinsong Road, Shanghai 201199, China. ²Department of Microbiological and Biochemical Pharmacy, School of Pharmacy, Fudan University, Shanghai 201203, China. ³Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia 19104, USA. ⁴Changhai Hospital, Second Military Medical University, Shanghai 200433, China. ⁵ImmuneOnco Biopharma (Shanghai) Co., Ltd., 1043 Halei Road, Shanghai 201203, China.

Received: 3 March 2019 Accepted: 11 November 2019

Published online: 11 December 2019

References

- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011;144:646–74.
- Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. *Nat Rev Drug Discov*. 2016;15:385–403.
- Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. *Nat Rev Cancer*. 2008;8:579–91.
- Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic therapy in oncology: current status and future directions. *Lancet*. 2016;388:518–29.
- Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. *CA Cancer J Clin*. 2017;67:507–24.
- Jain RK. Antiangiogenic strategies revisited: from starving tumors to alleviating hypoxia. *Cancer Cell*. 2014;26:605–22.
- Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. *Angiogenesis*. 2014;17:471–94.
- Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. *Nat Rev Cancer*. 2008;8:592–603.
- Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. *Sci Transl Med*. 2017. <https://doi.org/10.1126/scitranslmed.aak9679>.
- Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. *Immunity*. 2013;39:61–73.
- Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. *Nature*. 2011;480:480–9.
- Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. *Nat Immunol*. 2013;14:1014–22.
- Rivera LB, Meyronet D, Hervieu V, Frederick MJ, Bergsland E, Bergers G. Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. *Cell Rep*. 2015;11:577–91.
- Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. *Cancer Res*. 2013;73:539–49.
- Callahan MK, Postow MA, Wolchok JD. Targeting T cell co-receptors for cancer therapy. *Immunity*. 2016;44:1069–78.
- Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. *Cell*. 2015;161:205–14.
- Motz GT, Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. *Nat Rev Immunol*. 2011;11:702–11.
- Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. *Blood*. 1998;92:4150–66.
- Kandalafi LE, Motz GT, Busch J, Coukos G. Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin. *Curr Top Microbiol Immunol*. 2011;344:129–48.
- Zhang X, Fan J, Ju D. Insights into CD47/SIRPα axis-targeting tumor immunotherapy. *Antib Ther*. 2018;1:27–32.
- Vonderheide RH. CD47 blockade as another immune checkpoint therapy for cancer. *Nat Med*. 2015;21:1122–3.
- Piccione EC, Juarez S, Tseng S, Liu J, Stafford M, Narayanan C, et al. SIRPα-antibody fusion proteins selectively bind and eliminate dual antigen-expressing tumor cells. *Clin Cancer Res*. 2016;22:5109–19.
- Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, et al. The CD47-signal regulatory protein alpha (SIRPα) interaction is a therapeutic target for human solid tumors. *Proc Natl Acad Sci U S A*. 2012;109:6662–7.
- Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. *Cancer Cell*. 2015;27:462–72.
- Zhang X, Fan J, Wang S, Li Y, Wang Y, Li S, et al. Targeting CD47 and autophagy elicited enhanced antitumor effects in non-small cell lung cancer. *Cancer Immunol Res*. 2017;5:363–75.
- Zhang X, Chen W, Fan J, Wang S, Xian Z, Luan J, et al. Disrupting CD47-SIRPα axis alone or combined with autophagy depletion for the therapy of glioblastoma. *Carcinogenesis*. 2018;39:689–99.
- Liu L, Yu H, Huang X, Tan H, Li S, Luo Y, et al. A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity. *BMC Cancer*. 2015;15:170.
- Zhang X, Wang S, Nan Y, Fan J, Chen W, Luan J, et al. Inhibition of autophagy potentiated the anti-tumor effects of VEGF and CD47 bispecific therapy in glioblastoma. *Appl Microbiol Biotechnol*. 2018;102:6503.
- Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. *Cancer Cell*. 2005;8:299–309.
- Jimenez-Valerio G, Martinez-Lozano M, Bassani N, Vidal A, Ochoa-de-Olza M, Suarez C, et al. Resistance to Antiangiogenic therapies by metabolic Symbiosis in renal cell carcinoma PDX models and patients. *Cell Rep*. 2016;15:1134–43.
- Shen W, Zhang X, Fu X, Fan J, Luan J, Cao Z, et al. A novel and promising therapeutic approach for NSCLC: recombinant human arginase alone or combined with autophagy inhibitor. *Cell Death Dis*. 2017;8:e2720.
- Zhang B, Fan J, Zhang X, Shen W, Cao Z, Yang P, et al. Targeting asparagine and autophagy for pulmonary adenocarcinoma therapy. *Appl Microbiol Biotechnol*. 2016;100:9145–61.
- De Palma M, Venneri MA, Galli R, Sergi L, Politi LS, Sampaoli M, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. *Cancer Cell*. 2005;8:211–26.
- Rigamonti N, Kadioglu E, Keklikoglou I, Wyser Rmili C, Leow CC, De Palma M. Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. *Cell Rep*. 2014;8:696–706.
- Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. *Nat Biotechnol*. 2007;25:911–20.
- Alessi C, Scapulatempo Neto C, Viana CR, Vazquez VL. PD-1/PD-L1 and VEGF-A/VEGF-C expression in lymph node microenvironment and association with melanoma metastasis and survival. *Melanoma Res*. 2017;27:565–72.
- McCracken MN, Cha AC, Weissman IL. Molecular pathways: activating T cells after Cancer cell phagocytosis from blockade of CD47 “Don’t eat me” signals. *Clin Cancer Res*. 2015;21:3597–601.
- Gholamin S, Mitra SS, Feroze AH, Liu J, Kahn SA, Zhang M, et al. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. *Sci Transl Med*. 2017. <https://doi.org/10.1126/scitranslmed.aaf2968>.
- Russ A, Hua AB, Montfort WR, Rahman B, Riaz IB, Khalid MU, et al. Blocking “don’t eat me” signal of CD47-SIRPα in hematological malignancies, an in-depth review. *Blood Rev*. 2018;32:480–9.
- Betancur PA, Abraham BJ, Yiu YY, Willingham SB, Khameneh F, Zarnegar M, et al. A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer. *Nat Commun*. 2017;8:14802.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.